Monday, June 30, 2025 6/30/2025

Matching panels of in vivo and in vitro model system of pediatric brain tumors

Award Number: U01CA217613
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/03/2020
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

Matching panels of in vivo and in vitro model system of pediatric brain tumors - Project Summary Brain tumors are the leading cause of cancer-related death in children. Poor understanding of the interactions between tumor cells, especially cancer stem cells (CSCs), and normal brain tissues have played a role. Due to the difficulties of obtaining tumor tissues, there is a limited availability of biologically accurate and matched in vitro (tumor organoid) and in vivo (PDOX) model systems. Normal brain tissue is more difficult to obtain, making it nearly impossible to develop normal brain organoids. To overcome these barriers, we propose to utilize our existing (n=127) and future established patient derived orthotopic xenograft (PDOX) models as the source supply of tumor cells to develop matching tumor organoids. These PDOX models replicate the biology of original patient tumors and represent a wide spectrum of the newly discovered molecular subtypes of malignant brain tumors. Using 24 PDOX models, we have established 13 (54.1%) tumor organoids. Recognizing the rarity of normal brain tissues, we propose to use autopsied tissues. Indeed, we have cryopreserved viable cells of normal cerebrum, cerebellum, brain stem, and sub-ventricular zone cells from children of different ages and showed that the autopsied cerebral cells can proliferate in vitro to form neurospheres. We, therefore, hypothesize that 1) autopsied normal brain tissues and PDOX models can provide critically needed and biologically accurate cells for the development of normal and tumor organoid, and 2) the growth of these organoid are dependent on the growth factor milieu of their location and modulated by the dynamic interactions between different types of cells. Radiation therapy is one of the most important treatment regimens for pediatric brain tumors. Since mutation of histone modification genes are frequent in pediatric brain tumors, our 3rd hypothesis is that such epigenetic changes affect responses and resistance toward radiation, and successful targeting in organoid and PDOX tumors will lead to new combination therapies. We propose three Specific Aims. Aim 1: Develop normal brain organoids from autopsied normal cerebrum, cerebellum, brain stem and subventricle zone from all age groups and establish tumoral organoids from PDOX models and identify their location- and developmental-stage dependent niche factor combinations, respectively. Aim 2: Understand the dynamic interactions between tumor (CSCs and non-stem tumor) cells and normal brain cells. We will use co-culture assays to identify the niche factor combinations that dictate cellular diversity and survival of CSC and normal brain cells, and perform global multi-omics analysis and single cell RNAseq to elucidate the molecular mechanisms, followed by in vivo validation of our findings in PDOX models. Aim 3: Determine the role of histone methylation in regulating CSC survival and self-renewal of malignant brain tumors when perturbed by radiation. We will use normal and tumoral organoids to determine how pre-existing histone methylation status affect their survival and to identify key radiation-resistant methylation(s) by combining radiation with an informer set of small-molecule probes that selectively target distinct nodes in tumor epigenetic regulatory circuity in organoids and in PDOX models.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Cancer Biology Research	001	5	3/26/2025	NON-COMPETING CONTINUATION	$0
2025	2024	ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Cancer Biology Research	000	5	3/11/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $373,865 )
2024	2024	ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Cancer Biology Research	002	5	9/16/2024	NON-COMPETING CONTINUATION	$311,709
2024	2024	ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Cancer Biology Research	000	5	3/7/2024	NON-COMPETING CONTINUATION	$42,480
2024	2024	ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Cancer Biology Research	001	5	4/16/2024	NON-COMPETING CONTINUATION	$19,676
														Subtotal = $373,865

Issue Date FY: 2023 ( Subtotal = $291,655 )
2023	2023	ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Cancer Biology Research	000	4	2/28/2023	NON-COMPETING CONTINUATION	$291,655
														Subtotal = $291,655

Issue Date FY: 2022 ( Subtotal = $658,996 )
2022	2022	ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Cancer Biology Research	002	3	3/18/2022	NON-COMPETING CONTINUATION	$605,199
2022	2022	ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Cancer Biology Research	003	3	5/3/2022	NON-COMPETING CONTINUATION	$53,797
2022	2021	ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Cancer Biology Research	001	2	1/13/2022	NON-COMPETING CONTINUATION	$0
2022	2021	ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Cancer Biology Research	000	2	1/7/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $658,996

Issue Date FY: 2021 ( Subtotal = $677,141 )
2021	2021	ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Cancer Biology Research	000	2	2/18/2021	NON-COMPETING CONTINUATION	$677,141
														Subtotal = $677,141

Issue Date FY: 2020 ( Subtotal = $897,346 )
2020	2020	ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Cancer Biology Research	000	1	3/3/2020	NEW	$766,113
2020	2020	ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Cancer Biology Research	001	1	9/9/2020	NEW	$131,233
														Subtotal = $897,346

Grand Total All Awards = $2,899,003

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Matching panels of in vivo and in vitro model system of pediatric brain tumors

Award Number: U01CA217613

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/03/2020

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer